A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, September 29, 2014
Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication known as PML
The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc. lead product, IkT-001Pro (imatinib), to treat progressive multifocal leukoencephalopathy (PML).
According to the National Institute of Neurological Disorders and Stroke, PML affects the white matter of the brain usually through a virus known as Polyomavirus JC (JC virus). If left untreated, JC virus can destroy motor neurons and cognitive ability, eventually leading to death.Multiple sclerosis patients are particularly prone to PML due to their lowered immunity from their disease and use of certain drugs.
“Multiple sclerosis can be a very disabling disease. To date, Tysabri® is our most effective treatment,” explained Dr. Jeffrey B. English, Director of Clinical Research at the MS Center of Atlanta, in a news release. “Unfortunately, it carries a risk of a life threatening brain infection that can lead to PML. There are ways to screen for PML early, but we have no effective treatments for this disease.”
To address this need, Inhibikase has been researching and developing imatinib for delivery to patients with PML. Imatinib is a host-directed protein kinase inhibitor that interferes with JC virus replication. It has also been implicated in Novartis AG’s anti-cancer drug Gleevec® to treat blood and stomach cancers. To safely deliver imatinib to PML patients by reducing the required dose and side effects, Inhibikase formulated imatinib using its proprietary technology to make IkT-001Pro. “The anti-JC virus activity of imatinib cannot be achieved by simply altering the frequency or amount of Gleevec given to patients,” said Milton H. Werner, PhD, President and CEO of Inhibikase. “Early trial work has already shown this. To succeed, we’re talking reengineering how imatinib is absorbed and distributed in the body.”
Since Inhibikase is essentially developing a new drug, it must go through clinical trials, which can be a burden for diseases with small populations. “The Designation will enable resources for continued development, but more importantly the Designation provides an additional avenue for discussion with the FDA on the best path for bringing IkT-001Pro to market. PML is a rare side effect of at least 13 beneficial medications, and PML may also arise as a side effect of many more medications now in clinical development.”